{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:36:01Z","timestamp":1787027761431,"version":"build-2736575974"},"reference-count":96,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Qatar University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) patients has transitioned from the standard of care to a treatment option limited to those with unsatisfactory tyrosine kinase inhibitor (TKI) responses and advanced disease stages. In recent years, the threshold for undergoing HSCT has increased. Most CML patients now have life expectancies comparable to the general population, and therefore, the goal of therapy is shifting toward achieving treatment-free remission (TFR). While TKI discontinuation trials in CML show potential for achieving TFR, relapse risk is high, affirming allogeneic HSCT as the sole curative treatment. HSCT should be incorporated into treatment algorithms from the time of diagnosis and, in some patients, evaluated as soon as possible. In this review, we will look at some of the recent advances in HSCT, as well as its indication in the era of aiming for TFR in the presence of TKIs in CML.<\/jats:p>","DOI":"10.3390\/cancers16040754","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T06:19:59Z","timestamp":1707718799000},"page":"754","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings?"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7227-9042","authenticated-orcid":false,"given":"Ibrahim","family":"Elmakaty","sequence":"first","affiliation":[{"name":"College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Saglio","sequence":"additional","affiliation":[{"name":"Department of Clinical and Biological Sciences, University of Turin, 10124 Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2937-8838","authenticated-orcid":false,"given":"Murtadha","family":"Al-Khabori","sequence":"additional","affiliation":[{"name":"Hematology Department, Sultan Qaboos University, Muscat 123, Oman"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelrahman","family":"Elsayed","sequence":"additional","affiliation":[{"name":"College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1411-9462","authenticated-orcid":false,"given":"Basant","family":"Elsayed","sequence":"additional","affiliation":[{"name":"College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elmarasi","sequence":"additional","affiliation":[{"name":"College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4927-9888","authenticated-orcid":false,"given":"Ahmed Adel","family":"Elsabagh","sequence":"additional","affiliation":[{"name":"College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Awni","family":"Alshurafa","sequence":"additional","affiliation":[{"name":"Hematology Section, Medical Oncology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), Doha P.O. Box 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elrazi","family":"Ali","sequence":"additional","affiliation":[{"name":"Interfaith Medical Center, Brooklyn, NY 11213, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-8076","authenticated-orcid":false,"given":"Mohamed","family":"Yassin","sequence":"additional","affiliation":[{"name":"College of Medicine, QU Health, Qatar University, Doha P.O. Box 2713, Qatar"},{"name":"Hematology Section, Medical Oncology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation (HMC), Doha P.O. Box 3050, Qatar"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"key":"ref_1","first-page":"103295","article-title":"Understanding the hematopoietic microenvironment in chronic myeloid leukemia: A concise review","volume":"69","author":"Mayani","year":"2021","journal-title":"Curr. Res. Transl. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/315550a0","article-title":"Fused transcript of abl and bcr genes in chronic myelogenous leukaemia","volume":"315","author":"Shtivelman","year":"1985","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1016\/j.clml.2016.02.008","article-title":"When to Consider Allogeneic Transplantation in CML","volume":"16","author":"Radich","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1002\/cncr.10832","article-title":"Characteristics and outcome of patients with Philadelphia chromosome negative, bcr\/abl negative chronic myelogenous leukemia","volume":"95","author":"Onida","year":"2002","journal-title":"Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ajh.25792","article-title":"Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring","volume":"95","author":"Jabbour","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/ajh.27007","article-title":"Classification of accelerated phase chronic myeloid leukemia in the era of the BCR::ABL1 tyrosine kinase inhibitors: A work in progress","volume":"98","author":"Kantarjian","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","article-title":"Life Expectancy of Patients with Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population","volume":"34","author":"Bower","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1634\/theoncologist.2012-0197","article-title":"Decreasing trend in mortality of chronic myelogenous leukemia patients after introduction of imatinib in Japan and the U.S","volume":"17","author":"Chihara","year":"2012","journal-title":"Oncologist"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Daskalakis, M., Feller, A., Noetzli, J., Bonadies, N., Arndt, V., Baerlocher, G.M., and The Nicer Working, G. (2021). Potential to Improve Therapy of Chronic Myeloid Leukemia (CML), Especially for Patients with Older Age: Incidence, Mortality, and Survival Rates of Patients with CML in Switzerland from 1995 to 2017. Cancers, 13.","DOI":"10.3390\/cancers13246269"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2016.02.001","article-title":"Disease-related mortality exceeds treatment-related mortality in patients with chronic myeloid leukemia on second-line or later therapy","volume":"43","author":"Pearson","year":"2016","journal-title":"Leuk. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1586\/17474086.2015.1087843","article-title":"Transplant to treatment-free remission: The evolving view of \u2018cure\u2019 in chronic myeloid leukemia","volume":"8","author":"Yong","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1503\/cmaj.1011625","article-title":"Hematopoietic stem cell transplantation: A primer for the primary care physician","volume":"170","author":"Leger","year":"2004","journal-title":"CMAJ"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1182\/bloodadvances.2020001648","article-title":"Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults","volume":"4","author":"Symons","year":"2020","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s11899-996-0004-9","article-title":"The role of allogeneic stem cell transplantation for CML in the tyrosine kinase inhibitor era","volume":"1","author":"Cutler","year":"2006","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_19","unstructured":"Khaddour, K., Hana, C.K., and Mewawalla, P. (2023). StatPearls, StatPearls Publishing."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/JBM.S382090","article-title":"Chronic Myeloid Leukemia, from Pathophysiology to Treatment-Free Remission: A Narrative Literature Review","volume":"14","author":"Rinaldi","year":"2023","journal-title":"J. Blood Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1200\/JCO.2016.68.2914","article-title":"Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients with Chronic Myeloid Leukemia","volume":"35","author":"Etienne","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_22","first-page":"179","article-title":"Advances in hematopoietic stem cell transplantation in chronic myeloid leukemia","volume":"16","author":"Veldman","year":"2013","journal-title":"Discov. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1182\/hematology.2022000329","article-title":"Transplantation in CML in the TKI era: Who, when, and how?","volume":"2022","author":"Niederwieser","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1002\/cncr.24531","article-title":"Risk score for outcome after allogeneic hematopoietic stem cell transplantation: A retrospective analysis","volume":"115","author":"Gratwohl","year":"2009","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1365-2141.2004.04955.x","article-title":"Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants","volume":"125","author":"Passweg","year":"2004","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"4018","DOI":"10.1182\/blood-2010-01-263624","article-title":"Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase","volume":"115","author":"Pavlu","year":"2010","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1182\/blood.V97.6.1560","article-title":"Early detection of BCR-ABL transcripts by quantitative reverse transcriptase-polymerase chain reaction predicts outcome after allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"97","author":"Olavarria","year":"2001","journal-title":"Blood"},{"key":"ref_31","first-page":"S34","article-title":"Prognostic significance of EBMT score for chronic myeloid leukaemia patients in the era of tyrosine kinase inhibitor therapy: A retrospective study from the chronic malignancy working party of the european group for blood and marrow transplantation (EBMT)","volume":"49","author":"Milojkovic","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1182\/blood-2010-08-301341","article-title":"Three decades of transplantation for chronic myeloid leukemia: What have we learned?","volume":"117","author":"Pavlu","year":"2011","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1182\/blood-2002-02-0535","article-title":"Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase","volume":"101","author":"Or","year":"2003","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1182\/blood-2004-09-3544","article-title":"Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: An analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT","volume":"106","author":"Crawley","year":"2005","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/bloodadvances.2018024844","article-title":"Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia","volume":"2","author":"Chhabra","year":"2018","journal-title":"Blood Adv."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood-2007-04-085969","article-title":"Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia","volume":"110","author":"Kebriaei","year":"2007","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/nrclinonc.2015.193","article-title":"Allogeneic transplantation for CML in the TKI era: Striking the right balance","volume":"13","author":"Innes","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1705478","article-title":"Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia","volume":"38","author":"Krejci","year":"2006","journal-title":"Bone Marrow Transpl."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1182\/blood.V87.10.4473.bloodjournal87104473","article-title":"Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation","volume":"87","author":"Lin","year":"1996","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1080\/17474086.2017.1360180","article-title":"Insights into the management of chronic myeloid leukemia in resource-poor settings: A Mexican perspective","volume":"10","year":"2017","journal-title":"Expert Rev. Hematol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Experts in Chronic Myeloid Leukemia (2013). The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: From the perspective of a large group of CML experts. Blood, 121, 4439\u20134442.","DOI":"10.1182\/blood-2013-03-490003"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/10245332.2016.1182695","article-title":"The treatment of CML at an environment with limited resources","volume":"21","year":"2016","journal-title":"Hematology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/bloodadvances.2019000745","article-title":"Analysis of the cost-effectiveness of treatment strategies for CML with incorporation of treatment discontinuation","volume":"3","author":"Yamamoto","year":"2019","journal-title":"Blood Adv."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.bbmt.2016.02.015","article-title":"Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis","volume":"22","author":"Chaudhury","year":"2016","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/petr.12074","article-title":"The Treatment of Children Suffering from Chronic Myelogenous Leukemia: A Comparison of the Result of Treatment with Imatinib Mesylate and Allogeneic Hematopoietic Stem Cell Transplantation","volume":"17","author":"Hamidieh","year":"2013","journal-title":"Pediatr. Transplant."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e13664","DOI":"10.1111\/petr.13664","article-title":"Outcomes of allogenic hematopoietic cell transplantation for childhood chronic myeloid leukemia: Single-center experience","volume":"24","author":"Hafez","year":"2020","journal-title":"Pediatr. Transplant."},{"key":"ref_49","first-page":"36","article-title":"Efficacy of Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Phase CML Resistant or Intolerant to Tyrosine Kinase Inhibitors","volume":"15","author":"Yassine","year":"2022","journal-title":"Hematol.\/Oncol. Stem Cell Ther."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.bbmt.2018.09.029","article-title":"Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia","volume":"25","author":"Andolina","year":"2019","journal-title":"Biol. Blood Marrow Transplant. J. Am. Soc. Blood Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e26905","DOI":"10.1002\/pbc.26905","article-title":"Musculoskeletal complications following total body irradiation in hematopoietic stem cell transplant patients","volume":"65","author":"Jackson","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: Evaluation of its impact within a subgroup of the randomized German CML Study IV","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S58","DOI":"10.5045\/br.2023.2023035","article-title":"Treatment-free remission after discontinuation of imatinib, dasatinib, and nilotinib in patients with chronic myeloid leukemia","volume":"58","author":"Han","year":"2023","journal-title":"Blood Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1016\/j.ejca.2013.06.018","article-title":"Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: A randomised trial of the Dutch-Belgian Cooperative Trial for Haemato-Oncology (HOVON)","volume":"49","author":"Thielen","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: The prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/MOH.0b013e32835dd922","article-title":"The next questions in chronic myeloid leukaemia and their answers","volume":"20","author":"Marin","year":"2013","journal-title":"Curr. Opin. Hematol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Rea, D., Rousselot, P., Guilhot, F.O., Tulliez, M., Nicolini, F.E., Guerci-Bresler, A.s., Legros, L., Gardembas, M., Giraudier, S., and Guillerm, G. (2012). Discontinuation of Second Generation (2G) Tyrosine Kinase Inhibitors (TKI) in Chronic Phase (CP)-Chronic Myeloid Leukemia (CML) Patients with Stable Undetectable BCR-ABL Transcripts. Blood, 120.","DOI":"10.1182\/blood.V120.21.916.916"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3324\/haematol.2019.242891","article-title":"Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: When and for whom?","volume":"105","author":"Atallah","year":"2020","journal-title":"Haematologica"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Deininger, M., O\u2019Brien, S.G., Guilhot, F.o., Goldman, J.M., Hochhaus, A., Hughes, T.P., Radich, J.P., Hatfield, A.K., Mone, M., and Filian, J. (2009). International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib. Blood, 114.","DOI":"10.1182\/blood.V114.22.1126.1126"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"Apperley","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/asheducation.V2012.1.115.3798209","article-title":"Initial choice of therapy among plenty for newly diagnosed chronic myeloid leukemia","volume":"2012","author":"Marin","year":"2012","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S1470-2045(11)70201-7","article-title":"Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial","volume":"12","author":"Kantarjian","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.3324\/haematol.2011.052571","article-title":"Chronic myeloid leukemia: The basis of treatment for tomorrow","volume":"96","author":"Carella","year":"2011","journal-title":"Haematologica"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","article-title":"Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib","volume":"120","author":"Marin","year":"2012","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1586\/17474086.2013.849571","article-title":"Is there a role for allogeneic transplantation in chronic myeloid leukemia?","volume":"6","author":"Benyamini","year":"2013","journal-title":"Expert Rev. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.3389\/fonc.2019.01132","article-title":"Management of Chronic Myeloid Leukemia in Advanced Phase","volume":"9","author":"Bonifacio","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/leu.2015.73","article-title":"The EUTOS population-based registry: Incidence and clinical characteristics of 2904 CML patients in 20 European Countries","volume":"29","author":"Hoffmann","year":"2015","journal-title":"Leukemia"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/bjh.18370","article-title":"Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity","volume":"199","author":"Copland","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.beha.2009.07.006","article-title":"The blast phase of chronic myeloid leukaemia","volume":"22","author":"Silver","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/bmt.2011.194","article-title":"Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: A CIBMTR analysis","volume":"47","author":"Khoury","year":"2012","journal-title":"Bone Marrow Transpl."},{"key":"ref_74","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/cncr.22535","article-title":"Imatinib combined with mitoxantrone\/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis","volume":"109","author":"Fruehauf","year":"2007","journal-title":"Cancer"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/ajh.26833","article-title":"Outcomes after allogeneic hematopoietic cell transplant in patients diagnosed with blast phase of myeloproliferative neoplasms: A retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation","volume":"98","author":"Orti","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1111\/ctr.12779","article-title":"Transplantation from haploidentical donor is not inferior to that from identical sibling donor for patients with chronic myeloid leukemia in blast crisis or chronic phase from blast crisis","volume":"30","author":"Ma","year":"2016","journal-title":"Clin. Transpl."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/cncr.30864","article-title":"Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients","volume":"123","author":"Jain","year":"2017","journal-title":"Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1182\/blood-2022-162252","article-title":"Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry","volume":"140","author":"Brioli","year":"2022","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.16971","article-title":"A British Society for Haematology Guideline on the diagnosis and management of chronic myeloid leukaemia","volume":"191","author":"Smith","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1007\/s00277-015-2324-0","article-title":"Management of chronic myeloid leukemia in blast crisis","volume":"94","author":"Saussele","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11899-012-0149-7","article-title":"Allogeneic stem cell transplantation for chronic myeloid leukemia","volume":"8","author":"Pavlu","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clml.2013.08.008","article-title":"Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase","volume":"14","author":"Ohanian","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/leu.2012.92","article-title":"First-line imatinib mesylate in patients with newly diagnosed accelerated phase-chronic myeloid leukemia","volume":"26","author":"Rea","year":"2012","journal-title":"Leukemia"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/leu.2011.355","article-title":"Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results","volume":"26","author":"Giles","year":"2012","journal-title":"Leukemia"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3324\/haematol.13529","article-title":"The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: The GIMEMA CML Working Party experience after a 7-year follow-up","volume":"94","author":"Palandri","year":"2009","journal-title":"Haematologica"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1182\/blood-2010-09-308510","article-title":"Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phase","volume":"117","author":"Jiang","year":"2011","journal-title":"Blood"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1007\/s11684-015-0400-4","article-title":"Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase","volume":"9","author":"Xu","year":"2015","journal-title":"Front. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1182\/blood.V118.21.602.602","article-title":"Subset Analysis of Response to Treatment of Chronic Phase CML in a Phase 1 Study of Ponatinib in Refractory Hematologic Malignancies","volume":"118","author":"Cortes","year":"2011","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.bbmt.2016.03.012","article-title":"Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia","volume":"22","author":"Xu","year":"2016","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1002\/cncr.30558","article-title":"Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation","volume":"123","author":"Nicolini","year":"2017","journal-title":"Cancer"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"118","DOI":"10.4103\/0377-4929.40422","article-title":"Simultaneous appearance of dual malignancies of hematopoietic system-multiple myeloma and acute myeloid leukemia","volume":"51","author":"Shukla","year":"2008","journal-title":"Indian J. Pathol. Microbiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/bmt.2011.165","article-title":"Reduced-intensity allografting in patients with therapy-related myeloid neoplasms and active primary malignancies","volume":"46","author":"Valentin","year":"2011","journal-title":"Bone Marrow Transpl."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1182\/blood-2002-07-2053","article-title":"Emergence of clonal cytogenetic abnormalities in Ph\u2212cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority","volume":"101","author":"Bumm","year":"2003","journal-title":"Blood"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/bmt.2011.180","article-title":"Allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and concurrent lymphoid malignancy","volume":"47","author":"Zimmerman","year":"2012","journal-title":"Bone Marrow Transpl."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/754\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:58:46Z","timestamp":1760104726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/4\/754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":96,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["cancers16040754"],"URL":"https:\/\/doi.org\/10.3390\/cancers16040754","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]}}}